A new treatment for resistant hypertension using a long-lasting hormone.
A novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (hBNP), to treat resistant hypertension
This study is testing a new long-lasting treatment using a hormone called hBNP to help people with stubborn high blood pressure that doesn't respond well to regular medications, making it easier for them to manage their condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Antlia Bioscience INC NIH-funded |
| Lab location | 1 site (Encinitas, United States) |
| Project ID | NIH-10815642 on NIH RePORTER |
What this research studies
This research investigates a novel long-acting version of the hormone human brain natriuretic peptide (hBNP) to treat patients with resistant hypertension, a condition where blood pressure remains high despite treatment. The approach aims to enhance the effectiveness of hBNP, which naturally lowers blood pressure by promoting vasodilation and reducing fluid retention. By developing a formulation that allows for less frequent administration, the research seeks to improve patient adherence and outcomes. The study will involve monitoring the safety and efficacy of this new treatment in patients who struggle with traditional hypertension therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have resistant hypertension and have not achieved adequate blood pressure control with existing medications.
Not a fit: Patients who do not have hypertension or those whose condition is well-controlled with current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and convenient treatment option for patients with resistant hypertension.
How similar studies have performed: While the use of hBNP has been previously tested for short-term effects, this long-acting formulation represents a novel approach that has not been extensively studied.
Where this research is happening
Encinitas, United States
- Antlia Bioscience INC — Encinitas, United States (Active)
Researchers
- Principal investigator: Johnson, Brian Laurence — Antlia Bioscience INC
- Study coordinator: Johnson, Brian Laurence
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.